Eli Lilly hits $1 trillion market value, a first for a health-care company
The pharmaceutical giant Eli Lilly's stock has been riding the skyrocketing demand for its weight loss injection Zepbound and diabetes treatment Mounjaro.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.